Marshall P. Shaffer, P.C.

Kirkland & Ellis advised EW Healthcare Partners on a partnership with Ascend Advanced Therapies (Ascend), a gene-to-GMP development company, which will help to expand the footprint and capabilities of Ascend in the United States. As part of the broader transaction, EW Healthcare Partners also sold its portfolio company, Advanced BioScience Laboratories (ABL), a biotherapy, oncolytic and viral vector contract development, and manufacturing organization (CDMO) located in Rockville, Md., to Ascend and made a significant capital investment in Ascend in order to support the continued growth of the company. Read the transaction press release The Kirkland team included corporate lawyers Kimberly Snyder, Marshall Shaffer, Aprajita Dhundia and Matt Suhosky and tax lawyers Vivek Ratnam and Mike Beinus.

Nov 20

1 min

Home health and hospice provider Enhabit Inc., advised by Jones Day, on Monday unveiled plans to go private following a sale to middle market private equity firm Kinderhook Industries LLC, led by Kirkland & Ellis LLP, in an all-cash deal valued at roughly $1.1 billion. Under the terms of the agreement, Kinderhook will pay $13.80 per share for Enhabit, representing a roughly 24.4% premium to the company's closing stock price on Friday, according to a Monday statement. Once the deal closes, Enhabit will delist its shares from the New York Stock Exchange. "Following a thorough evaluation and extensive deliberations in consultation with our independent advisers, we are pleased to reach this agreement with Kinderhook," said Enhabit Chairman Jeffrey Bolton. "The board evaluated the current state of the business, its outlook and opportunities, and is confident this transaction maximizes value for our stockholders and is in their best interest." Enhabit is a national home health and hospice provider with a nationwide footprint of 249 home health locations and 117 hospice locations across 34 states. Kinderhook said it has secured financing for the deal, with a debt financing commitment letter from "certain lenders" and equity commitment letters from Kinderhook-advised funds, the statement said. "We have long admired Enhabit's leadership, patient-centric culture and strong market position in home-based care. Kinderhook has a successful 20-year track record of investing in industry-leading companies and partnering with world-class management teams," said Kinderhook Managing Director Chris Michalik. "Enhabit exemplifies exactly the kind of organization we seek to support — and the kind of team we are excited to partner with," Michalik said. Once the deal closes, Enhabit will continue to operate under its name and brand. The deal is expected to close in the second quarter of 2026, subject to shareholder approval and regulatory approvals. The Jones Day team advising Enhabit was led by partners Andy Levine and Darcy White and included partner Ferrell Keel. The Kirkland team advising Kinderhook included corporate partners Marshall Shaffer, Tom Marbury, Steven Choi and Kartik Khanna; debt finance partners Yongjin Im and Justin Greer; executive compensation partner Stephen Brecher; healthcare partners Dennis Williams and Micah Desaire; tax partner Ben Schreiner; antitrust and competition partners Ian John and Sam Morelli; employee benefits partner Chris Chase; labor and employment partner Mari Stonebraker; and technology and IP transactions partner Daisy Darvall.

Feb 23

2 min

Home health and hospice provider Enhabit Inc., advised by Jones Day, on Monday unveiled plans to go private following a sale to middle market private equity firm Kinderhook Industries LLC, led by Kirkland & Ellis LLP, in an all-cash deal valued at roughly $1.1 billion. Under the terms of the agreement, Kinderhook will pay $13.80 per share for Enhabit, representing a roughly 24.4% premium to the company's closing stock price on Friday, according to a Monday statement. Once the deal closes, Enhabit will delist its shares from the New York Stock Exchange. "Following a thorough evaluation and extensive deliberations in consultation with our independent advisers, we are pleased to reach this agreement with Kinderhook," said Enhabit Chairman Jeffrey Bolton. "The board evaluated the current state of the business, its outlook and opportunities, and is confident this transaction maximizes value for our stockholders and is in their best interest." Enhabit is a national home health and hospice provider with a nationwide footprint of 249 home health locations and 117 hospice locations across 34 states. Kinderhook said it has secured financing for the deal, with a debt financing commitment letter from "certain lenders" and equity commitment letters from Kinderhook-advised funds, the statement said. "We have long admired Enhabit's leadership, patient-centric culture and strong market position in home-based care. Kinderhook has a successful 20-year track record of investing in industry-leading companies and partnering with world-class management teams," said Kinderhook Managing Director Chris Michalik. "Enhabit exemplifies exactly the kind of organization we seek to support — and the kind of team we are excited to partner with," Michalik said. Once the deal closes, Enhabit will continue to operate under its name and brand. The deal is expected to close in the second quarter of 2026, subject to shareholder approval and regulatory approvals. The Jones Day team advising Enhabit was led by partners Andy Levine and Darcy White and included partner Ferrell Keel. The Kirkland team advising Kinderhook included corporate partners Marshall Shaffer, Tom Marbury, Steven Choi and Kartik Khanna; debt finance partners Yongjin Im and Justin Greer; executive compensation partner Stephen Brecher; healthcare partners Dennis Williams and Micah Desaire; tax partner Ben Schreiner; antitrust and competition partners Ian John and Sam Morelli; employee benefits partner Chris Chase; labor and employment partner Mari Stonebraker; and technology and IP transactions partner Daisy Darvall.

Feb 23

2 min

Kirkland & Ellis advised Crown Laboratories, Inc., a privately held, global innovative leader in the skincare industry, on a definitive merger agreement to purchase Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings. The acquisition was announced August 12, 2024 and is expected to close by the end of the year. Under the terms of the agreement, which has been unanimously approved by Revance’s Board of Directors, Crown will commence a tender offer to acquire all outstanding shares of Revance’s common stock for $6.66 per share in cash for an overall value of $924 million. The purchase price represents a premium of 89% over Revance’s closing market price on August 7, 2024, and a 111% premium to Revance’s 60-day volume-weighted average price. Read the transaction press release The Kirkland team was led by corporate partners Marshall Shaffer and Ed Lee, along with Josh Kogan, Andrew Norwich and Steven Choi and associates Monica Ruiz and Matthew Burner; investment funds partners Jordan Murray, Juliet Anderson and Justin Samson and associate Chris Stoj; debt finance partners Jason Kanner, Chad Davis and Angela Hagerman and associates Kaitlin Schock and Daly Brower; executive compensation partners Scott Price and Anthony Ji and associate Grace Zagorskis; capital markets partners Julia Danforth and Pippa Bond and associate Van Whiting and Sarah Yang; and antitrust & competition associate Mariana del Carmen Fernandez.

Aug 12

1 min

Kirkland advised Commure, Inc., a General Catalyst portfolio company, on signing a definitive agreement for the take-private acquisition of Augmedix, Inc., a firm focused on ambient AI medical documentation and data solutions. Commure, Inc. will leverage synergies from the acquisition to continue to grow its platform in healthcare technology. The acquisition was announced July 19, 2024 and is scheduled to close in late Q3 or early Q4, 2024. Read the transaction press release The team was led by corporate partner Marshall Shaffer and associates Davi Sacco and George Colligan, with assistance from corporate partners Christian Atwood and Dave Gusella.

Jul 19

1 min